BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Insulin degludec: Phase IIIa data

The open-label, international Phase IIIa NN1250-3583 trial in 629 Type I diabetics showed that once-daily subcutaneous insulin degludec met the primary endpoint of non-inferiority to Lantus insulin glargine in reducing HbA1c from baseline to week 52 (0.4% reduction for both). Degludec also...

Read the full 197 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >